logo
'Looking good for postpartum' isn't the compliment we think it is—Kylie Kelce has a better idea

'Looking good for postpartum' isn't the compliment we think it is—Kylie Kelce has a better idea

Yahoo21-07-2025
On her podcast Not Gonna Lie, Kylie Kelce highlights how the common praise moms receive after birth can be harmful, especially when it focuses on the pressure to quickly 'bounce back.'
From stretch marks to strength, she's reframing how we talk about real recovery.
Kylie Kelce has four kids, a podcast, and zero time for toxic compliments.
On a recent episode of Not Gonna Lie, she opened up about a familiar postpartum experience—being told you 'look amazing' after birth. And while she knows it's meant to be encouraging, she's asking us to think twice.
'For all of the people who are in the comments saying things like, 'You look fantastic after having Finn' or 'You look amazing after having your fourth'… First of all, I know that you mean that nicely, but at the end of the day, if I looked like this and I hadn't just had my fourth child, would you say I look tired? Because yes, I'm very tired.'
Related: Kylie Kelce's dos and don'ts for talking to postpartum moms (because some of y'all need a reminder)
It's a moment that hits. Because most moms have heard it: 'You look great for just having a baby!' And while it might sound positive, Kelce gently pulls the thread on what these comments really say about our expectations of women after birth.
'My point is that we don't need to comment on the fact that a woman is postpartum and how she is doing with her postpartum journey physically. And I think we should be more concerned about the overall well-being of women postpartum. I don't think that we need to bounce back.'
Stretch marks, strength, and saying what we mean
In a moment that will resonate with anyone navigating their postpartum body, Kelce shares:
'There are some things that we, as women who have just grown humans, cannot bounce back. I can't bounce back my stretch marks. They're with me forever. Do I like them? Let's be honest, no. I liked when my tummy didn't have a bunch of little ridges in it. But guess what? It does. Do I still look damn good? Yes.'
There's no performative body positivity here. Just real talk about the duality so many moms feel—pride in what their bodies have done, and grief over how those bodies have changed.
Related: Kylie Kelce shuts down harmful claim that C-sections aren't 'real' births
A cultural shift—and a call to reframe
Kelce's honesty taps into a larger conversation about postpartum care, body image, and the quiet pressure to 'recover' in ways that center appearance instead of health. That pressure often shows up in well-meaning comments—especially on social media.
Kelce suggests that paying attention to how a mom is feeling matters more than focusing on her appearance.
In the same episode, Mandy Moore shares her own experience navigating labels like 'geriatric pregnancy,' which reflects another layer of judgment and bias in maternal care. But what ties it all together is the need to center moms—not metrics or milestones—in every part of the postpartum journey.
As Kelce puts it, the changes motherhood brings are not setbacks but experiences to embrace and grow from.
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications
FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

Yahoo

time24 minutes ago

  • Yahoo

FibroBiologics Files Patent for Methods of Generating Multipotent Cells from Donor Tissue for Clinical Applications

HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ('FibroBiologics'), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods of generating multipotent cells from fibroblasts found in donor tissue for clinical applications. Multipotency refers to a flexible cellular state in which a cell has the potential to differentiate into multiple specialized cell types, depending on the environmental conditions or stimuli it encounters. While stem cells have garnered the most attention on being multipotent, fibroblasts are also considered multipotent and can be directly differentiated into many cell types including chondrocytes, osteocytes, hepatocytes and cardiomyocytes. This patent application broadly relates to methods for generating multipotent cells directly from fibroblasts found in human donor tissues. 'This method provides us with the ability to obtain larger quantities of stable and easily scalable multipotent cells from donor-derived fibroblasts for use in clinical applications,' said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. 'Multipotent fibroblasts also show enhanced ability to form 3D spheroid structures, further expanding their potential across a range of therapeutic and drug development areas.' Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, said, 'By enabling the generation of stable, multipotent cells directly from donor tissue, this innovation addresses long-standing challenges in the field and opens new possibilities for scalable, regenerative treatments.' For more information, please visit FibroBiologics' website or email FibroBiologics at info@ Cautionary Statement Regarding Forward-Looking Statements This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of multipotent fibroblasts across a range of therapeutic and drug development areas and new possibilities for scalable, regenerative treatments. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations. About FibroBiologics Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 275+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit General Inquiries:info@ Investor Relations:Nic JohnsonRusso Partners(212) 845-4242fibrobiologicsIR@ Media Contact:Liz PhillipsRusso Partners(347) in to access your portfolio

Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio
Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

Yahoo

time24 minutes ago

  • Yahoo

Dexcom Launches Revolutionary AI-Powered Meal Logging Feature Across Glucose Biosensing Portfolio

The new AI-powered Smart Food Logging feature supports greater personalized insights into how meals are impacting glucose levels Users can now take a photo of their food in their Stelo or Dexcom G7 app where AI will automatically identify the ingredients and populate the meal description SAN DIEGO, July 28, 2025--(BUSINESS WIRE)--DexCom, Inc., the global leader in glucose biosensing, announced today it has released a new AI-powered photo meal logging feature to Stelo, the first over-the-counter glucose biosensor cleared1 by the FDA in the United States, following the feature's launch on Dexcom G7 earlier this year. Dexcom's Smart Food Logging feature encourages and enables users to log their meals more consistently. Stelo and Dexcom G7 users can now simply take a photo of their food in the app where AI will automatically identify the ingredients and populate the meal description. Dexcom G7 is the only prescription continuous glucose monitor in the U.S. to support photo logging2,3. "Diet plays a crucial role in managing glucose levels, and our new Smart Food Logging feature removes barriers to food tracking, making it easier to consistently log and understand the impact of meals," said Jake Leach, president and chief operating officer at Dexcom. "Smart Food Logging has long been a highly requested feature from users across our product portfolio, so we're excited to bring it to market and hope this enhanced tracking feature makes managing glucose levels even simpler." The addition of Smart Food Logging is yet another demonstration of Dexcom's commitment to continued innovation and AI. This new feature joins other recently announced enhancements across Dexcom's glucose biosensing portfolio, including: Weekly Insights in Stelo: The first GenAI feature in Stelo, which offers users more personalized tips, recommendations, and education related to diet, exercise, and sleep that are contextualized within the Stelo app. Stelo integration with Oura: The first-ever integration of glucose biosensing data in the Oura app. When Stelo is synced with Oura, users have a holistic view of their body's biometrics, now including glucose. This integration empowers users to understand the impact of different health behaviors and work towards optimal metabolic health. Customizable target range in Dexcom G7: A new feature that enables users to adjust their glucose target ranges in Clarity Card within the Dexcom G7 app, beyond default settings – allowing for greater personalization across user groups. Glucose Impact in Dexcom G7 and Stelo: Glucose Impact offers a new focused view for logged events to see a clearer picture and gain a deeper understanding of how meals, activities, and sleep patterns affect your glucose levels. Stelo and Dexcom G7 users can now access the Smart Food Logging feature by updating to the latest version of the app on iOS and Android platforms. About DexCom, Inc. Dexcom empowers people to take control of health through innovative biosensing technology. Founded in 1999, Dexcom has pioneered and set the standard in glucose biosensing for more than 25 years. Its technology has transformed how people manage diabetes and track their glucose, helping them feel more in control and live more confidently. Dexcom. Discover what you're made of. For more information, visit Category: IR 1 Dexcom, Stelo User Guide, 2024. 2 Based on Freestyle Libre User Guides. 3 Based on Medtronic User Guides. View source version on Contacts Media Relations Contact Nadia Conardmediarelations@ Investor Relations Contact Sean Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

A Practical Look At How To Solve The Blood Supply Problem
A Practical Look At How To Solve The Blood Supply Problem

Forbes

time29 minutes ago

  • Forbes

A Practical Look At How To Solve The Blood Supply Problem

Bob Roda is the President and CEO of Hemosonics. Many people are familiar with food deserts—areas where it is difficult to obtain fresh, healthy food like produce and vegetables—but far fewer are familiar with blood deserts, places where blood supplies are scarce or even sometimes nonexistent. According to a recent article published by Harvard Medical School, "Billions of people live in 'blood deserts,' areas in which the clinical need for blood components cannot be met in at least 75 percent of cases." A blood shortage could prove disastrous in life-threatening cases where a patient needs blood in minutes. Blood deserts aren't just located abroad; numerous rural communities in the U.S. don't have access to crucial blood supplies. Many groups, including the Blood D.E.S.E.R.T. Coalition, have organized to combat the challenge. Hospitals and healthcare organizations, such as the Red Cross, have responded with additional calls for blood donations. While blood donations provide a crucial pipeline for blood supplies, they cannot fix the problem. Emerging technology, hospital culture change and community activism, however, could provide critical help in the short term as experts work on systemic changes to boost blood supply in challenged areas. Experts say it will take decades to recover from the blood shortage in the U.S. alone. Here are four short-term strategies to adopt now to help address blood deserts. 1. Change the culture of thinking around transfusions. Transfusions are a critical life-saving resource, particularly for victims of severe body trauma like industrial accidents and automobile wrecks. However, many have made strong arguments that transfusions are overused. In reality, transfusion is often unnecessary, and patients will do fine with their own blood. There are challenges to this, like longstanding medical practices. But when a transfusion is avoided, blood is saved for a patient who needs it. 2. Embrace patient blood management (PBM). Four years ago, the World Health Organization (WHO) called for healthcare systems worldwide to implement patient blood management (PBM) as a standard of care. The adoption of PBM continues to lag, however, particularly in U.S. hospitals. In short, PBM is a systematic, evidence-based approach that improves patient outcomes by preserving a patient's own blood and promoting safety and empowerment. PBM has three critical tenets: Use the patient's blood, minimize blood loss and improve a patient's anemia tolerance. Patient blood management has been transformative in conserving blood supplies at hospitals worldwide. The only challenge is changing the existing medical culture and protocols around blood use and transfusion. Hospitals should embrace the practice to increase blood supplies. 3. Adopt new technologies. Technological advances and new tools may offer the best chance to help underdeveloped blood deserts in the short term. Chief among them are viscoelastic testing systems. These tests identify whether a patient is at risk for bleeding, the type of blood product they may require and the amount of blood needed. (Full disclosure: My company, HemoSonics, manufactures Quantra, a viscoelastic testing system.) One of the most frequent causes of hospital trauma death is uncontrolled bleeding. However, many of these fatalities are potentially preventable with early, targeted hemostatic intervention. Some technological obstacles include the initial cost of purchasing the technology and training. However, according to the WHO, hospitals that implement viscoelastic testing find they quickly preserve blood, improve patient outcomes, reduce hospital readmissions and reoperations and lower hospital and healthcare facility costs. Other new technologies could also make a difference. Zipline, for example, delivers blood and other critical medical supplies via drones from hospitals and urban areas to blood deserts in Rwanda. There are also 'walking blood banks': new backpack-size kits that contain everything remote medical personnel need to collect and then transfuse blood. Finally, AI and machine learning are also promising: What they do exceedingly well is identify patterns and data and extract crucial findings about blood usage. The findings enable blood banks to allocate resources more effectively and earmark blood donations for underserved areas. AI can also help quickly match a patient with available blood supply, minimizing labor and ensuring patients receive the necessary blood product fast. 4. Utilize mobile blood collection. When blood is collected, it is typically transported to a central site in an urban area for safe storage. Another promising answer to blood deserts is a more targeted use of blood donations. For example, patients in certain areas organize to collect blood for a remote hospital in need. Blood supplies could also be collected and then earmarked for geographic areas where supplies are scarce. Blood donors could also be identified and contacted during a critical regional shortage. The existence of blood deserts is a multilayered social and economic problem that has as much to do with fundamental economic inequities as it does with medical practices. Truly fixing blood deserts will require economic development, improving transportation and supply chains and ensuring an equitable allocation of resources. Nonetheless, the practices above shouldn't be considered just a short-term fix, but rather part of a collective effort to eradicate blood deserts. Combining technology, strategy, activism and public service is a major step in the right direction to conserve blood supplies and address the problem. Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store